Mucus, cough and chronic lung disease: New discoveries
As a cold ends, a severe mucus cough starts. Sound familiar? Two studies now give explanations: First, crucial mechanisms of the mucus in...
AzurRx BioPharma Receives Sanction of Cystic Fibrosis Therapeutics Development Network for the Study
On track to initiate Phase 2 trial in cystic fibrosis patients in the fourth quarter of 2018 and conclude in 2019 NEW YORK, Nov. 01, 2018...
#NACFC2018 — Vertex Presents Latest Clinical Data on CFTR Modulators
Vertex Pharmaceuticals’ VX-659 or VX-445 in combination with Kalydeco(ivacaftor) and tezacaftor (VX-661) can improve the lung function of...
PTI-808 and PTI-801 Combo Improves Lung Function in CF Patients, Phase 1 Data Show
Treatment with a combo of Proteostasis Therapeutics’ investigational CFTR modulator therapies — PTI-808, a potentiator, plus PTI-801, a...
Proteostasis Therapeutics' Double and Triple-Combo CF Drugs Possible Threat to Vertex Dominance
Boston-based Proteostasis Therapeutics announced positive preliminary data from its ongoing Phase I clinical trial of PTI-808 and PTI-801...
Scientists Reveal New Cystic Fibrosis Treatments Work Best in Inflamed Airways
New UNC School of Medicine research led by Martina Gentzsch, PhD, and Carla Ribeiro, PhD, suggests that cystic fibrosis drugs used to...
Understanding antibiotic resistance in patients with cystic fibrosis
A defective gene causes thick, sticky mucus to build up in the lungs of patients with cystic fibrosis (CF). There, it traps bacteria,...
#NACFC — Sound Pharmaceuticals to Present Preliminary Data on Ototoxicity Study
Sound Pharmaceuticals (SPI) will present data on the incidence and severity of ototoxicity in cystic fibrosis (CF) patients who received...
Vertex and Treating CF: High Hopes for Triple Combinations and Gene Therapy Possibilities
Editor’s note: This is third in a four-part series looking at Vertex Pharmaceuticals and its “all in for CF” approach. Here, we look at...
Does Monotherapy With Correctors Have Clinical Benefit in Cystic Fibrosis?
Insufficient evidence exists to demonstrate that monotherapy with correctors has clinically important effects in individuals with cystic...
